Atrial tachycardia is an arrhythmia with electrical impulses originating within the atria. Atrial tachycardia can be a result of one or a combination of the mechanisms leading to arrhythmia: automatic, triggered activity, or reentry. In some cases, the mechanism remains undetermined. Electrophysiologic features may overlap if there is a small reentrant circuit, as in micro-reentry. It is useful to categorize atrial tachycardia in two broad groups: macroreentrant or focal.
The prototypic macroreentrant atrial tachycardia is an atrial flutter. Typical atrial flutter arises from the right atrium in a circuit bound anteriorly by the tricuspid annulus and posteriorly by the crista terminalis and Eustachian ridge. The electrical activity can travel in a clockwise or counterclockwise direction in this circuit.
Atrial flutter is a complex arrhythmia with different management than focal atrial tachycardias. As such, the focus of this activity will be on focal atrial tachycardia (FAT).
Atrial tachycardia tends to occur in individuals with structural heart disease, with or without heart failure, and ischemic coronary artery disease. However, focal atrial tachycardia often occurs in healthy individuals without structural heart disease. Other possible etiologies are listed below:
The prevalence of focal atrial tachycardia is not well known. A European study of young males applying for pilot licenses demonstrated that 0.34% had symptomatic atrial tachycardia and 0.46% had symptomatic atrial tachycardia. A study noted 10 to 15% of patients presenting for supraventricular tachycardia ablation had atrial tachycardia.
Focal atrial tachycardias can arise from any or a combination of the three mechanisms causing tachyarrhythmias: enhanced automaticity, triggered, or reentry. Reentry is typically the underlying mechanism in macro-reentrant atrial tachycardias like atrial flutter. If a reentrant mechanism is involved in a focal atrial tachycardia, it involves a micro-reentrant circuit which can be difficult to distinguish from an automatic focus on surface ECG. Reentry involves adjacent substrate with different electrophysiologic properties. In a simplified version; tissue type A must have both different conduction velocity and rate of repolarization (electrical recovery) from tissue type B. As electricity propagates through types A and B at different rates, an early electrical stimulus may encounter type A recovered and type B refractory. The signal then transverses through type A and subsequently finds type B recovered, establishing a reentrant circuit. Reentry may be readily induced during an electrophysiology study.
Focal atrial tachycardia often occurs as a result of abnormal automaticity and are challenging to initiate during an electrophysiology study and require drug infusion to induce. Abnormal automaticity arises from spontaneous phase 4 depolarization.
During phase 4, the cardiac myocyte membrane is polarized and at baseline. The inwardly rectifying potassium channel is responsible for maintaining baseline resting potential near potassium equilibrium.
Abnormal automaticity occurs as a result of accelerated phase 4 upslope, leading to spontaneously depolarizing cells. When the cell experiences further hyperpolarization, and more negative than -70 mV, automaticity may occur via the "funny" current, carried by sodium and potassium ions in sinoatrial, AV nodal, and His-Purkinje cells.
The triggered activity has features seen with enhanced automaticity, though are felt to primarily involve calcium channels. Similar to reentry, triggered activity is inducible during an electrophysiology study.
A detailed history and physical are necessary for every patient, which should include home medications, as well as past medical and surgical history. Also, a social history which should consist of past or present tobacco use, alcohol use, and if the patient consumes caffeine, illicit drugs, or stimulants. A past medical history significant for chronic lung disease, pulmonary hypertension, or other conditions can predispose the patient to atrial tachycardia. Chronic alcohol use or withdrawal can also be associated with atrial tachycardia. Cardiac surgeries can lead to atrial tissue scarring that may be arrhythmogenic.
Patients can present with atrial tachycardias in various ways. Atrial tachycardia can present on telemetry of patients who may be asymptomatic or asleep. As focal atrial tachycardias tend to occur secondary to an underlying disease process, the patient presentation will reflect primary chief complaints.
Patients with atrial tachycardia may complain of palpitations or sensations of fast heart rate, lightheadedness, chest pain or pressure, or shortness of breath. Symptom intensity will be related to the rate as well as the patient’s cardiovascular status. The patient may complain of irregular heart rate if the patient’s tachycardia is sufficient to produce an intermittent AV block.
Symptoms may occur in paroxysms or can be persistent. Symptoms may be related to the consumption of caffeinated products (including coffee, tea, energy drinks or chocolate) or stimulants like ephedrine. Symptoms can also be initiated or exacerbated by stress and exercise. Adenosine administration may cause transient AV block, but does not terminate focal atrial tachycardia.
Persistent focal atrial tachycardia can result in cardiomyopathy, which may lead to symptoms of dyspnea with exertion, increased lower extremity edema, and chest pain. Although the clinical course is typically benign, there is some risk of sudden cardiac death.
The physical exam can demonstrate regular or irregular tachycardia with a heart rate greater than 100 BPM. If the patient’s atrial tachycardia includes a variable block, the intensity of S1 may vary from beat to beat. Excessive A waves may be present on observation of the jugular venous pulse.
EKG can aid the diagnosis of focal atrial tachycardia. EKG features may also inform the origin of focal atrial tachycardias. Electrocardiographic features include:
Initial management of focal atrial tachycardia should focus on addressing underlying causes: treating acute illness, cessation of stimulants, stress reduction, appropriately managing digoxin toxicity, or chronic disease management. The ventricular rate is controllable with the use of beta blockers or calcium channel blockers. If atrial tachyarrhythmia persists and the patient is symptomatic, the patient may benefit from class IA, IC, or class III antiarrhythmics. Of course, risks and benefits of using antiarrhythmic medications should be considered, especially in patients with ischemic or structural heart disease. Catheter ablation of focal atrial tachycardia may be appropriate in patients failing medical therapy.,. As the driver of many focal atrial tachycardias is by enhanced automaticity, electrical cardioversion without concurrent medical therapy as listed previously will likely result in arrhythmia recurrence.
Focal atrial tachycardia may be challenging to distinguish from other regular, narrow complex tachycardias. Furthermore, atrial tachycardias may demonstrate some irregularity during “warm-up” and “warm-down” phases, which may further prove difficult to differentiate. Atrial tachycardia is associated with a narrow complex QRS in the absence of aberrant conduction to the ventricles or bundle branch blocks.
As the management of focal atrial tachycardia differs from other narrow complex regular tachycardias, distinguishing focal atrial tachycardia from other supraventricular tachyarrhythmias is important. Below is a differential of similar appearing arrhythmias with their identifying features.
Narrow complex, regular tachycardias
Narrow complex, irregular tachycardia
Focal atrial tachycardia is a benign rhythm. Overall prognosis depends on conditions precipitating this arrhythmia. However, if atrial tachycardia persists, it can lead to tachycardia-induced cardiomyopathies over time. If there is a concern for a high burden of tachyarrhythmias, patients should undergo monitoring as an outpatient with a Holter monitor or outpatient/mobile telemetry. Medications should be adjusted as described above.
Risk factors for arrhythmia are similar to risk factors for developing heart disease. A heart-healthy lifestyle with a well-balanced diet, exercising and refraining from tobacco products is essential for prevention. Focal atrial tachycardia persistence can be mitigated by the avoidance of caffeinated products and other stimulant substances.
Atrial tachycardia can produce symptoms such as palpitations, lightheadedness, and pre-syncope, which can understandably generate anxiety. It is therefore essential to convey to patients that although atrial tachycardia can be bothersome, it is not a lethal arrhythmia.
Diagnosis of atrial arrhythmias is reliant on detection. Cardiac telemetry must be used judiciously and appropriately monitored. Healthcare professionals should understand the indications for initiating and discontinuing cardiac telemetry. Appropriate personnel should monitor telemetry and obtain 12-lead ECG’s to aid in the diagnosis of dysrhythmia when they occur.
Proper management of atrial tachycardia requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]
|||Buttà C,Tuttolomondo A,Giarrusso L,Pinto A, Electrocardiographic diagnosis of atrial tachycardia: classification, P-wave morphology, and differential diagnosis with other supraventricular tachycardias. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2015 Jul [PubMed PMID: 25530184]|
|||Thomas D,Eckardt L,Estner HL,Kuniss M,Meyer C,Neuberger HR,Sommer P,Steven D,Voss F,Bonnemeier H, [Typical atrial flutter: Diagnosis and therapy]. Herzschrittmachertherapie & Elektrophysiologie. 2016 Mar [PubMed PMID: 26846223]|
|||Poutiainen AM,Koistinen MJ,Airaksinen KE,Hartikainen EK,Kettunen RV,Karjalainen JE,Huikuri HV, Prevalence and natural course of ectopic atrial tachycardia. European heart journal. 1999 May; [PubMed PMID: 10208790]|
|||Steinbeck G,Hoffmann E, 'True' atrial tachycardia. European heart journal. 1998 May; [PubMed PMID: 9717019]|
|||Ng FS,Guerrero F,Luther V,Sikkel M,Lim PB, Microreentrant left atrial tachycardia circuit mapped with an ultra-high-density mapping system. HeartRhythm case reports. 2017 Apr [PubMed PMID: 28491807]|
|||Kiedrowicz RM,Podd S,O'Neill M, Focal automaticity manifesting as incessant right atrial tachycardia. Heart rhythm. 2016 Apr [PubMed PMID: 26690064]|
|||Baruscotti M,Bianco E,Bucchi A,DiFrancesco D, Current understanding of the pathophysiological mechanisms responsible for inappropriate sinus tachycardia: role of the If "funny" current. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2016 Jun [PubMed PMID: 26781742]|
|||Leonelli F,Bagliani G,Boriani G,Padeletti L, Arrhythmias Originating in the Atria. Cardiac electrophysiology clinics. 2017 Sep [PubMed PMID: 28838547]|
|||Ju W,Yang B,Li M,Zhang F,Chen H,Gu K,Yu J,Cao K,Chen M, Tachycardiomyopathy complicated by focal atrial tachycardia: incidence, risk factors, and long-term outcome. Journal of cardiovascular electrophysiology. 2014 Sep [PubMed PMID: 24716793]|
|||Qian ZY,Hou XF,Xu DJ,Yang B,Chen ML,Chen C,Zhang FX,Shan QJ,Cao KJ,Zou JG, An algorithm to predict the site of origin of focal atrial tachycardia. Pacing and clinical electrophysiology : PACE. 2011 Apr [PubMed PMID: 21091746]|
|||Rosso R,Kistler PM, Focal atrial tachycardia. Heart (British Cardiac Society). 2010 Feb [PubMed PMID: 19443472]|
|||Busch S,Forkmann M,Kuck KH,Lewalter T,Ince H,Straube F,Wieneke H,Julian Chun KR,Eckardt L,Schmitt C,Hochadel M,Senges J,Brachmann J, Acute and long-term outcome of focal atrial tachycardia ablation in the real world: results of the german ablation registry. Clinical research in cardiology : official journal of the German Cardiac Society. 2018 May [PubMed PMID: 29344680]|
|||Leong KMW,Guerrero F,Lim PB, Cavotricuspid-Isthmus Dependent Flutter or Left-Sided Atrial Tachycardia? The Journal of invasive cardiology. 2017 Aug [PubMed PMID: 28756424]|
|||Gupta S,Figueredo VM, Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. International journal of cardiology. 2014 Mar 1 [PubMed PMID: 24447747]|
|||[PubMed PMID: 22188716]|